A Randomized-Controlled Trial of the Efficacy, Safety and Tolerability of Intravitreal Brolucizumab in Patients With Chronic Central Serous Chorioretinopathy With Persistent Fluid in the Absence of Choroidal Neovascular Membrane-BRICS Trial Report II.
- DOI
- 10.1016/j.ajo.2025.12.007
- Published
- 2026 Mar
- Container
- American journal of ophthalmology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ajo.2025.12.007,
title = {A Randomized-Controlled Trial of the Efficacy, Safety and Tolerability of Intravitreal Brolucizumab in Patients With Chronic Central Serous Chorioretinopathy With Persistent Fluid in the Absence of Choroidal Neovascular Membrane-BRICS Trial Report II.},
author = {Ramamurthy SR and Hansraj S and Kumar R and Narula R and Sadda SR and Sivaprasad S and Chhablani JK and Tyagi M and Reddy NG and Behera UC and Narayanan R},
year = {2026},
journal = {American journal of ophthalmology},
doi = {10.1016/j.ajo.2025.12.007},
url = {https://doi.org/10.1016/j.ajo.2025.12.007}
}RIS
TY - JOUR TI - A Randomized-Controlled Trial of the Efficacy, Safety and Tolerability of Intravitreal Brolucizumab in Patients With Chronic Central Serous Chorioretinopathy With Persistent Fluid in the Absence of Choroidal Neovascular Membrane-BRICS Trial Report II. AU - Ramamurthy SR AU - Hansraj S AU - Kumar R AU - Narula R AU - Sadda SR AU - Sivaprasad S AU - Chhablani JK AU - Tyagi M AU - Reddy NG AU - Behera UC AU - Narayanan R PY - 2026 JO - American journal of ophthalmology DO - 10.1016/j.ajo.2025.12.007 UR - https://doi.org/10.1016/j.ajo.2025.12.007 ER -
APA
SR, R., S, H., R, K., R, N., SR, S., S, S., JK, C., M, T., NG, R., UC, B., & R, N. (2026). A Randomized-Controlled Trial of the Efficacy, Safety and Tolerability of Intravitreal Brolucizumab in Patients With Chronic Central Serous Chorioretinopathy With Persistent Fluid in the Absence of Choroidal Neovascular Membrane-BRICS Trial Report II.. American journal of ophthalmology. https://doi.org/10.1016/j.ajo.2025.12.007
Source records
- pubmed · retrieved 2026-09-26T20:23:29.333Z